Thomas Barnard, MD
Ophthalmology · Lake Mary, FLNPI 1487654117
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,536 of the $7,426 with a category attached, or 61.1%. 15 manufacturers reported payments, led by US Retina LLC at 37.6% of the total. Reporting peaked in 2023 at $2,334 and has fallen 54.0% since, to $1,074 in 2025.
Across 207 payments — averaging $35.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$3K
- Regeneron Healthcare Solutions, Inc.$1K
- Alimera Sciences, Inc.$836
- Genentech USA, Inc.$731
- Apellis Pharmaceuticals, Inc.$508
- AbbVie$468
- plus $1K from 9 others
What the payments were for
- Food & beverage$4,53661%
- Education$981%
- Ownership interest$1,13015%
- Other$1,66322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $2,792 |
| Regeneron Healthcare Solutions, Inc. | 50 | $1,022 |
| Alimera Sciences, Inc. | 33 | $836 |
| Genentech USA, Inc. | 30 | $731 |
| Apellis Pharmaceuticals, Inc. | 19 | $508 |
| AbbVie(2 entities) | 16 | $468 |
| ANI Pharmaceuticals, Inc. | 11 | $283 |
| Astellas Pharma US Inc | 17 | $240 |
| Mallinckrodt Hospital Products Inc. | 5 | $149 |
| Novartis | 7 | $145 |
| Eyepoint US, Inc. | 7 | $100 |
| Coherus Oncology, Inc. | 2 | $64 |
| Harrow Eye, LLC | 2 | $51 |
| Sandoz | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,426 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 109 | $271,584 |
| VabysmoFaricimab-Svoa | 29 | $83,877 |
| SyfovrePegcetacoplan/Pf | 18 | $65,700 |
| RestasisCyclosporine | 15 | $13,391 |
| Prednisolone Acetate | 339 | $12,163 |
| LumiganBimatoprost | 15 | $4,326 |
| Latanoprost | 270 | $3,061 |
| Loteprednol Etabonate | 23 | $2,936 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 142 | $1,811 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 122 | $1,632 |
| Timolol Maleate | 137 | $1,573 |
| Brimonidine Tartrate | 170 | $1,208 |
| Brinzolamide | 11 | $1,130 |
| Atropine Sulfate | 23 | $781 |
| ValacyclovirValacyclovir Hcl | 13 | $723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $1,022 | $271,584109 claims |
| Genentech USA, Inc.Vabysmo | $731 | $83,87729 claims |
| Apellis Pharmaceuticals, Inc.Syfovre | $508 | $65,70018 claims |
| AbbVieRestasis, Lumigan | $468 | $17,71730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Lake Mary
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.